EUROFINS CLINICAL TRIAL SUPPLIES FRANCE : revenue, balance sheet and financial ratios

EUROFINS CLINICAL TRIAL SUPPLIES FRANCE is a French company founded 7 years ago, specialized in the sector Analyses, essais et inspections techniques. Based in NANTES (44300), this company of category GE shows in 2024 a revenue of 4.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - EUROFINS CLINICAL TRIAL SUPPLIES FRANCE (SIREN 844974121)
Indicator 2024 2023 2022 2021 2020 2019
Revenue 4 342 652 € 4 219 192 € 4 099 537 € 3 455 240 € N/C N/C
Net income 255 069 € 194 075 € 317 134 € 20 736 € -12 370 € -10 449 €
EBITDA 374 947 € 201 153 € 158 334 € 111 551 € -12 376 € -10 449 €
Net margin 5.9% 4.6% 7.7% 0.6% N/C N/C

Revenue and income statement

In 2024, EUROFINS CLINICAL TRIAL SUPPLIES FRANCE achieves revenue of 4.3 M€. Over the period 2021-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +7.9%. Vs 2023: +3%. After deducting consumption (43 k€), gross margin stands at 4.3 M€, i.e. a rate of 99%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 375 k€, representing 8.6% of revenue. Positive scissor effect: EBITDA margin improves by +3.9 pts, sign of improved operational efficiency. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 255 k€, i.e. 5.9% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

4 342 652 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

4 299 530 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

374 947 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

380 336 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

255 069 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

8.6%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 190%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 25%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 6.6 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 5.6% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

190.039%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

24.666%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

5.63%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

6.612

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

52.5%

Solvency indicators evolution
EUROFINS CLINICAL TRIAL SUPPLIES FRANCE

Sector positioning

Debt ratio
190.04 2024
2022
2023
2024
Q1: 0.0
Med: 9.99
Q3: 48.5
Average +17 pts over 3 years

In 2024, the debt ratio of EUROFINS CLINICAL TRIAL S... (190.04) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
24.67% 2024
2022
2023
2024
Q1: 11.63%
Med: 34.78%
Q3: 58.76%
Average -12 pts over 3 years

In 2024, the financial autonomy of EUROFINS CLINICAL TRIAL S... (24.7%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
6.61 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.0 years
Q3: 0.87 years
Watch

In 2024, the repayment capacity of EUROFINS CLINICAL TRIAL S... (6.61) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 235.75. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 36.5x. Operating income very largely covers interest expenses: high safety margin.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

235.745

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

36.517

Liquidity indicators evolution
EUROFINS CLINICAL TRIAL SUPPLIES FRANCE

Sector positioning

Liquidity ratio
235.75 2024
2022
2023
2024
Q1: 133.14
Med: 205.95
Q3: 337.03
Good +21 pts over 3 years

In 2024, the liquidity ratio of EUROFINS CLINICAL TRIAL S... (235.75) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Interest coverage
36.52x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.02x
Q3: 2.48x
Excellent

In 2024, the interest coverage of EUROFINS CLINICAL TRIAL S... (36.5x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 62 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 41 days. The company must finance 21 days of gap between collections and payments. Inventory turnover is 5 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 117 days of revenue, i.e. 1.4 M€ to permanently finance.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

1 409 451 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

62 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

41 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

5 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

117 j

WCR and payment terms evolution
EUROFINS CLINICAL TRIAL SUPPLIES FRANCE

Positioning of EUROFINS CLINICAL TRIAL SUPPLIES FRANCE in its sector

Comparison with sector Analyses, essais et inspections techniques

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (41 transactions). This range of 256 006€ to 2 121 050€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2024
Indicative
256k€ 1256k€ 2121k€
1 256 828 € Range: 256 006€ - 2 121 050€
NAF 5 année 2024

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 41 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Analyses, essais et inspections techniques)

Compare EUROFINS CLINICAL TRIAL SUPPLIES FRANCE with other companies in the same sector:

Voir toutes les statistiques du secteur Analyses, essais et inspections techniques

Frequently asked questions about EUROFINS CLINICAL TRIAL SUPPLIES FRANCE

What is the revenue of EUROFINS CLINICAL TRIAL SUPPLIES FRANCE ?

The revenue of EUROFINS CLINICAL TRIAL SUPPLIES FRANCE in 2024 is 4.3 M€.

Is EUROFINS CLINICAL TRIAL SUPPLIES FRANCE profitable?

Yes, EUROFINS CLINICAL TRIAL SUPPLIES FRANCE generated a net profit of 255 k€ in 2024.

Where is the headquarters of EUROFINS CLINICAL TRIAL SUPPLIES FRANCE ?

The headquarters of EUROFINS CLINICAL TRIAL SUPPLIES FRANCE is located in NANTES (44300), in the department Loire-Atlantique.

Where to find the tax return of EUROFINS CLINICAL TRIAL SUPPLIES FRANCE ?

The tax return of EUROFINS CLINICAL TRIAL SUPPLIES FRANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does EUROFINS CLINICAL TRIAL SUPPLIES FRANCE operate?

EUROFINS CLINICAL TRIAL SUPPLIES FRANCE operates in the sector Analyses, essais et inspections techniques (NAF code 71.20B). See the 'Sector positioning' section above to compare the company with its competitors.